This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/chemspider/
n29http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n21http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/kegg-compound/
n20http://www.rxlist.com/cgi/generic/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/pubchem-substance/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n30http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/property/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/drugbank/
n5http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00251/identifier/national-drug-code-directory/
n27http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00251
rdf:type
n3:Drug
n3:description
Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia]
n3:dosage
n7:271B3EB5-363D-11E5-9242-09173F13E4C5 n7:271B3EB6-363D-11E5-9242-09173F13E4C5 n7:271B3EB7-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
6.9 hours (range 4.0-11.3)
n3:indication
For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.
n3:manufacturer
n13:271B3EA9-363D-11E5-9242-09173F13E4C5 n13:271B3EA7-363D-11E5-9242-09173F13E4C5 n13:271B3EA8-363D-11E5-9242-09173F13E4C5 n13:271B3EA5-363D-11E5-9242-09173F13E4C5 n13:271B3EA6-363D-11E5-9242-09173F13E4C5 n13:271B3EA4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00251 n21:DB00251
dcterms:title
Terconazole
adms:identifier
n9:46505257 n10:441383 n11:D00888 n12:0168-0347-20 n14:Terconazole n18:PA164768834 n24:C08080 n25:390122 n26:DB00251
n3:mechanismOfAction
Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.
n3:packager
n13:271B3E93-363D-11E5-9242-09173F13E4C5 n13:271B3E94-363D-11E5-9242-09173F13E4C5 n13:271B3E97-363D-11E5-9242-09173F13E4C5 n13:271B3E98-363D-11E5-9242-09173F13E4C5 n13:271B3E95-363D-11E5-9242-09173F13E4C5 n13:271B3E96-363D-11E5-9242-09173F13E4C5 n13:271B3E9B-363D-11E5-9242-09173F13E4C5 n13:271B3E9C-363D-11E5-9242-09173F13E4C5 n13:271B3E99-363D-11E5-9242-09173F13E4C5 n13:271B3E9A-363D-11E5-9242-09173F13E4C5 n13:271B3E9F-363D-11E5-9242-09173F13E4C5 n13:271B3EA0-363D-11E5-9242-09173F13E4C5 n13:271B3E9D-363D-11E5-9242-09173F13E4C5 n13:271B3E9E-363D-11E5-9242-09173F13E4C5 n13:271B3EA3-363D-11E5-9242-09173F13E4C5 n13:271B3EA1-363D-11E5-9242-09173F13E4C5 n13:271B3EA2-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.
n3:synonym
Terazol 3
n3:toxicity
The oral LD<sub>50</sub> values were found to be 1741 and 849 mg/kg for the male and female in rat.
n22:hasAHFSCode
n23:84-04-08-08
n3:proteinBinding
94.9%
n28:hasConcept
n29:M0114183
foaf:page
n5:ter1436.shtml n20:tercon.htm n30:terconazole-cream.html
n3:IUPAC-Name
n6:271B3EBC-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B3EC2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B3EC1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B3EBE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B3EBF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B3EC0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B3EBA-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B3EB8-363D-11E5-9242-09173F13E4C5 n6:271B3EBB-363D-11E5-9242-09173F13E4C5 n6:271B3ED2-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B3EB9-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n27:G01AG02
n3:H-Bond-Acceptor-Count
n6:271B3EC8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B3EC9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B3EC3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B3EC4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B3EC6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B3EC5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B3EC7-363D-11E5-9242-09173F13E4C5
n3:absorption
Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations
n3:affectedOrganism
Fungi
n3:casRegistryNumber
67915-31-5
n3:category
n3:containedIn
n19:271B3EAB-363D-11E5-9242-09173F13E4C5 n19:271B3EAC-363D-11E5-9242-09173F13E4C5 n19:271B3EAA-363D-11E5-9242-09173F13E4C5 n19:271B3EAF-363D-11E5-9242-09173F13E4C5 n19:271B3EB0-363D-11E5-9242-09173F13E4C5 n19:271B3EAD-363D-11E5-9242-09173F13E4C5 n19:271B3EAE-363D-11E5-9242-09173F13E4C5 n19:271B3EB3-363D-11E5-9242-09173F13E4C5 n19:271B3EB4-363D-11E5-9242-09173F13E4C5 n19:271B3EB1-363D-11E5-9242-09173F13E4C5 n19:271B3EB2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B3ECD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B3ECF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B3ED0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B3ED1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B3ECC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B3ECB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B3ECE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B3EBD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B3ECA-363D-11E5-9242-09173F13E4C5